David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains whether or not variant cells pre-exist…
Browsing: Acute Lymphoblastic Leukemia
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the transformation of cancers into stem-cell…
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics gives an overview of his abstract, Rb1…
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses the treatment trends for prostate cancer…
Toni Choueiri, MD and David McDermott, MD discusses the Immuno-Oncology: Changing the Treatment Landscape in RCC at the 12th European…
Börje Ljungberg from UmeÃ¥ University Sweden discusses the Development of Guidelines in a Rapidly Changing Treatment Landscape for the John…
Bernard Escudier of the Gustave Roussy discusses Brain mets under I.O. at the 12th European International Kidney Cancer Symposium 2017
Guillermo de Velasco MD, PhD University Hospital 12 de Octubre discusses SBRT for lung metastases: Case report at the 12th…
Manuela Schmidinger of the Medical University of Vienna discusses the Solitary Bone Mets Spinal at the 12th European International Kidney…
Camillo Porta, MD of the I.R.C.C.S. San Matteo University Hospital Foundation answers the question How should the next generation of…
Gabriel Malouf, MD, PhD of Pitié-Salpêtrière Hospital Defines Optimal 2nd Line Treatment and Sequence: Biomarker at the 12th European International…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Eric P.…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Dawn L.…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Constantine Godellas…
David McDermott, MD of the Dana-Farber/Harvard Cancer Center outlines and Defines Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from…
John B.A.G. Haanen MD PhD of the The Netherlands Cancer Institute discusses Anti-PD1 PDL1 + anti-VEGFR in Kidney Cancer at…
Toni K. Choueiri, MD of the Dana-Farber Cancer Institute discusses the changes in first line kidney cancer treatment for 2018…
Thomas Powles MD of Barts Cancer Institute discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib…
Hans Hammers, MD, PhD, UT Southwestern discusses the Dual Immune Checkpoint Blockade at the  12th European International Kidney Cancer Symposium…
Alain Ravaud, MD.PhD takes the pro side of the debate entitled Adjuvant Therapy Ready For Prime Time In Kidney Cancer…
Tanja de Gruijl, VU University Medical Center discusses Harnessing the sentinel lymph node Translational perspective: LN as the first priming…
Prof. Dr. med. Viktor Grünwald of the Medical School Hannover outlines the Oncologists perspective LN as metastatic spread at the…
Jose A. Karam, MD, FACS, Associate Professor Department of Urology MD Anderson Cancer Center discusses Surgeons Perspective: LN as a…
Aung Naing of MD Anderson Cancer Center discusses PEGylated Human IL-10 AM0010 in Combination with Nivolumab in Renal Cell Cancer…
Cynthia Macahilig of the University of Manchester discusses Health-Related Quality of Life, Treatment Satisfaction, and Work Productivity for Patients With…
Hans J. Hammers, MD of the University of Texas Southwestern Medical Center discusses Updated Results From a Phase I Study…
Krzysztof Krawczyk of the Department of Translational Medicine, Center for Molecular Pathology Lund University, Malmö, Sweden discusses the papillary renal…
Saeed Dabestani MD PhD student Lund University, Sweden discusses the Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes a RECUR…
Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam discusses the Challenges in Surgical Trials for Kidney Cancer…
In this activity, meeting co-chair Dr. John P. Leonard provides the key take-home messages from the leukemia, myeloid disorders, and…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Kathy S.…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Debu Tripathy…
In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Hope S.…
In this activity, meeting co-chair Dr. David P. Steensma provides the key take-home messages from the leukemia, myeloid disorders, and…
In this activity, meeting co-chair Dr. Robert Z. Orlowski provides the key take-home messages from the plasma cell disorder session…
Dr. Arnaud Mejean, MD presents the challenges in CARMENA from the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany
Dr. Thomas Powles, MD presents the Challenges in Neoadjuvant Biomarker Trials at the 2017 12th Annual European Kidney Cancer Symposium,…
Axel Bex, MD presents Challenges In Surtime at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany   …
Dr. Cora Sternberg, MD presents the P.H.M. deMulder Lecture entitled From cytokines to targeted therapies to immunotherapy30 years of progress…
Bernard J. Escudier, MD introduces Dr. Cora Sternberg, MD before the P.J.M. dMulder Lecture at the 12th Annual European Kidney…
Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the treatment trends for lymphoma in 2017, which include…
Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an overview of his presentation, CHRONOS-1, which shows the…
Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an update on immunotherapy, which was a hot topic…
Martin Dreyling, MD of University of Munich Hospital in Grosshadern explains the difference between copanlisib and other PI3K inhibitors, specifically…
Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the impact of his clinical trial, CHRONOS-1, on current…
Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the treatment trends in 2017 for his field, neuro-oncology, which include…
Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of the AACR presentations, which show more data and…
Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how intracellular targets are detected onto the cell surface. He states…
Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how the clinical data will help better characterize which patients respond…
Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the impact his clinical trial has on clinicians and future research.…